The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms
Open accessAbstract
BACKGROUND: Approximately 50 to 60% of patients with essential thrombocythemia or primary myelofibrosis carry a mutation in the Janus kinase 2 gene (JAK2), and an additional 5 to 10% have activating mutations in the thrombopoietin receptor gene (MPL). So far, no specific molecular marker has been identified in the remaining 30 to 45% of patients. METHODS: We performed whole-exome sequencing to identify somatically acquired mutations in six patients who had primary myelofibrosis without mutations in JAK2 or MPL. Resequencing of CALR, encoding calreticulin, was then performed in cohorts of patients with myeloid neoplasms. RESULTS: Somatic insertions or deletions in exon 9 of CALR were detected in all patients who underwent whole-exome sequencing. Resequencing in 1107 samples from patients with myeloproliferative neoplasms showed that CALR mutations were absent in polycythemia vera. In essential thrombocythemia and primary myelofibrosis, CALR mutations and JAK2 and MPL mutations were mutually exclusive. Among patients with essential thrombocythemia or primary myelofibrosis with nonmutated JAK2 or MPL, CALR mutations were detected in 67% of those with essential thrombocythemia and 88% of those with primary myelofibrosis. A total of 36 types of insertions or deletions were identified that all cause a frameshift to the same alternative reading frame and generate a novel C-terminal peptide in the mutant calreticulin. Overexpression of the most frequent CALR deletion caused cytokine-independent growth in vitro owing to the activation of signal transducer and activator of transcription 5 (STAT5) by means of an unknown mechanism. Patients with mutated CALR had a lower risk of thrombosis and longer overall survival than patients with mutated JAK2. CONCLUSIONS: Most patients with essential thrombocythemia or primary myelofibrosis that was not associated with a JAK2 or MPL alteration carried a somatic mutation in CALR. The clinical course in these patients was more indolent than that in patients with the JAK2 V617F mutation. (Funded by the MPN Research Foundation and Associazione Italiana per la Ricerca sul Cancro.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Calreticulin gene (CALR) mutations frequently occur in Philadelphia chromosome (Ph)-negative myeloproliferative neoplasms (MPNs), including essential thrombocythemia (ET), primary myelofibrosis (PMF), and polycythemia vera (PV) [188–190].”
From Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies (2020) · cites this paper as [189]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
Swerdlow, S. H. (2017) · Medical Entomology and Zoology · Cited by 12,933
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
James, C., Ugo, V., Couedic, J. P. L., Staerk, J., Delhommeau, F., Lacout, C., Garçon, L., Raslová, H., Berger, R., Griscelli, A. B., et al. (2005) · Nature · doi:10.1038/nature03546 · Cited by 3,542
A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders
Kralovics, R., Passamonti, F., Buser, A. S., Teo, S.-S., Tiedt, R., Passweg, J. R., Tichelli, A., Cazzola, M., & Skoda, R. C. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051113 · Cited by 3,470
Self-citationMutation in TET2 in Myeloid Cancers
Delhommeau, F., Dupont, S., Valle, V. D., James, C., Trannoy, S., Massé, A., Kosmider, O., Le Couedic, J.-P., Robert, F., Alberdi, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810069 · Cited by 1,776
MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia
Pikman, Y., Lee, B. H., Mercher, T., McDowell, E. P., Ebert, B. L., Gozo, M. C., Cuker, A. C., Wernig, G., Moore, S. A., Galinsky, I. A., et al. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030270 · Cited by 1,445
JAK2 Exon 12 Mutations in Polycythemia Vera and Idiopathic Erythrocytosis
Scott, L. M., Tong, W., Levine, R. L., Scott, M., Beer, P., Stratton, M. R., Futreal, P., Erber, W., McMullin, M., Harrison, C. N., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065202 · Cited by 1,346
The Analysis of Failure Times in the Presence of Competing Risks
Prentice, R. L., Kalbfleisch, J. D., Peterson, A. V., Flournoy, N., Farewell, V. T., & Breslow, N. E. (1978) · Biometrics · doi:10.2307/2530374 · Cited by 1,266
Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders
Ernst, T., Chase, A. J., Score, J., Hidalgo-Curtis, C. E., Bryant, C., Jones, A. V., Waghorn, K., Zoi, K., Ross, F. M., Reiter, A., et al. (2010) · Nature Genetics · doi:10.1038/ng.621 · Cited by 1,139
Passamonti, F., Cervantes, F., Vannucchi, A. M., Morra, E., Rumi, E., Pereira, A., Guglielmelli, P., Pungolino, E. M., Caramella, M., Maffioli, M., et al. (2009) · Blood · doi:10.1182/blood-2009-09-245837 · Cited by 997
Self-citationMutations and prognosis in primary myelofibrosis
Vannucchi, A. M., Lasho, T. L., Guglielmelli, P., Biamonte, F., Pardanani, A. D., Pereira, A., Finke, C. M., Score, J., Gangat, N., Mannarelli, C., et al. (2013) · Leukemia · doi:10.1038/leu.2013.119 · Cited by 793
Self-citation
Cited by
Sorted by citations
Items 501–600 of 1,001
Dhamija, S., Yang, C. M., Seiler, J., Myacheva, K., Caudron‐Herger, M., Wieland, A., Abdelkarim, M., Sharma, Y., Riester, M., Groß, M., et al. (2020) · Nature Cell Biology · doi:10.1038/s41556-020-0551-7 · Cited by 29
Precision medicine in myeloid malignancies
Westermann, J., & Bullinger, L. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.03.034 · Cited by 29
Inferring the initiation and development of myeloproliferative neoplasms
Hermange, G., Rakotonirainy, A., Bentriou, M., Tisserand, A., El-Khoury, M., Girodon, F., Marzac, C., Vainchenker, W., Plo, I., & Cournède, P.-H. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2120374119 · Cited by 33
Calreticulin (CALR) mutation in myeloproliferative neoplasms (MPNs).
Luo, W., & Yu, Z. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2306-9759.2015.08.01 · Cited by 29
Minimal residual disease testing in hematologic malignancies and solid cancer
Lassoued, A. B., Nivaggioni, V., & Gabert, J. A. (2014) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2014.927311 · Cited by 29
Barraco, D., Elala, Y. C., Lasho, T. L., Begna, K. H., Gangat, N., Finke, C. M., Hanson, C. A., Ketterling, R. P., Pardanani, A. D., & Tefferi, A. (2016) · Blood Cancer Journal · doi:10.1038/bcj.2016.22 · Cited by 29
New molecular genetics in the diagnosis and treatment of myeloproliferative neoplasms
Passamonti, F., Mora, B., & Maffioli, M. (2016) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000218 · Cited by 29
Incidence, Survival and Prevalence Statistics of Classical Myeloproliferative Neoplasm in Korea
Lim, Y., Lee, J., & Bang, S. (2016) · Journal of Korean Medical Science · doi:10.3346/jkms.2016.31.10.1579 · Cited by 30
The myeloproliferative neoplasms, unclassifiable: clinical and pathological considerations
Gianelli, U., Cattaneo, D., Bossi, A., Cortinovis, I., Boiocchi, L., Liu, Y.-C., Augello, C., Bonometti, A., Fiori, S., Orofino, N., et al. (2016) · Modern Pathology · doi:10.1038/modpathol.2016.182 · Cited by 29
Molecular testing for JAK 2, MPL , and CALR in myeloproliferative neoplasms
Xia, D., & Hasserjian, R. P. (2016) · American Journal of Hematology · doi:10.1002/ajh.24578 · Cited by 31
Vasko, T., Kaifie, A., Stope, M. B., Kraus, T., & Ziegler, P. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18112267 · Cited by 31
Papadopoulos, N., Nédélec, A., Derenne, A., Şulea, T. A., Pecquet, C., Chachoua, I., Vertenoeil, G., Tilmant, T., Petrescu, A., Mazzucchelli, G., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37277-3 · Cited by 30
Harada‐Shirado, K., Ikeda, K., Ogawa, K., Ohkawara, H., Kimura, H., Kai, T., Noji, H., Morishita, S., Komatsu, N., & Takeishi, Y. (2014) · British Journal of Haematology · doi:10.1111/bjh.13129 · Cited by 28
Immunotherapy in Myeloproliferative Diseases
Braun, L. M., & Zeiser, R. (2020) · Cells · doi:10.3390/cells9061559 · Cited by 28
Clonal Hematopoiesis and Mutations of Myeloproliferative Neoplasms
Kjær, L. (2020) · Cancers · doi:10.3390/cancers12082100 · Cited by 30
Allain‐Maillet, S., Bosseboeuf, A., Mennesson, N., Bostoën, M., Dufeu, L., Choi, E. H. E., Cleyrat, C., Mansier, O., Lippert, É., Bris, Y. L., et al. (2020) · Cancers · doi:10.3390/cancers12092446 · Cited by 29
Prins, D., Park, H. J., Watcham, S., Li, J., Vacca, M., Bastos, H. P., Gerbaulet, A., Vidal‐Puig, A., Göttgens, B., & Green, A. R. (2020) · Science Advances · doi:10.1126/sciadv.abd3139 · Cited by 30
Liu, J., Lv, B., Yin, H., Zhu, X., Wei, H., & Ding, Y. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.604314 · Cited by 28
Sollazzo, D., Forte, D., Polverelli, N., Romano, M., Perricone, M., Rossi, L., Ottaviani, E., Luatti, S., Martinelli, G., Vianelli, N., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9949 · Cited by 29
Recent advances in the understanding of myelodysplastic syndromes with ring sideroblasts
Malcovati, L., & Cazzola, M. (2016) · British Journal of Haematology · doi:10.1111/bjh.14215 · Cited by 29
Self-citationHobbs, G. S., Rozelle, S. S., & Mullally, A. (2017) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2017.04.002 · Cited by 30
Rocca, S., Carrà, G., Poggio, P., Morotti, A., & Brancaccio, M. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0774-4 · Cited by 28
Cancer Immune Therapy for Philadelphia Chromosome-Negative Chronic Myeloproliferative Neoplasms
Holmström, M. O., Hasselbalch, H. C., & Andersen, M. H. (2020) · Cancers · doi:10.3390/cancers12071763 · Cited by 28
Pemmaraju, N., Gupta, V. K., Mesa, R. A., & Thompson, M. A. (2015) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-015-0287-9 · Cited by 27
Safety evaluation of ruxolitinib for treating myelofibrosis
Galli, S., McLornan, D. P., & Harrison, C. N. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.916273 · Cited by 28
Dahlström, J., Liu, T., Yuan, X., Saft, L., Ghaderi, M., Wei, Y. B., Lavebratt, C., Li, P., Zheng, C., Björkholm, M., et al. (2016) · Annals of Hematology · doi:10.1007/s00277-016-2787-7 · Cited by 27
The relevance of a low JAK2V617F allele burden in clinical practice: a monocentric study
Perricone, M., Polverelli, N., Martinelli, G., Catani, L., Ottaviani, E., Zuffa, E., Franchini, E., Dizdari, A., Forte, D., Sabattini, E., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.16744 · Cited by 27
Guglielmelli, P., Pietra, D., Pane, F., Pancrazzi, A., Cazzola, M., Vannucchi, A. M., Tura, S., & Barosi, G. (2017) · Leukemia Research · doi:10.1016/j.leukres.2017.04.006 · Cited by 27
Self-citationPedersen, R. K., Andersen, M., Knudsen, T. A., Sajid, Z., Gudmand‐Hoeyer, J., Dam, M. J. B., Skov, V., Kjær, L., Ellervik, C., Larsen, T. S., et al. (2020) · Cancer Medicine · doi:10.1002/cam4.2741 · Cited by 28
Pegliasco, J., Hirsch, P., Marzac, C., Isnard, F., Meniane, J.-C., Deswarte, C., Pellet, P., Lemaitre, C., Leroy, G., Moraes, G. R., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01319-w · Cited by 27
Jutzi, J. S., Marneth, A. E., Jiménez‐Santos, M. J., Hem, J. W., Guerra-Moreno, Á., Rolles, B., Bhatt, S., Myers, S. A., Carr, S. A., Hong, Y., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01781-0 · Cited by 27
Chronic neutrophilic leukemia: a clinical perspective
Cigudosa, J. C., & Menezes, J. (2015) · OncoTargets and Therapy · doi:10.2147/ott.s49688 · Cited by 27
Bioinformatic analyses of CALR mutations in myeloproliferative neoplasms support a role in signaling
Eder‐Azanza, L., Navarro, D., Aranaz, P., Novo, F. J., Cross, N. C. P., & Vizmanos, J. L. (2014) · Leukemia · doi:10.1038/leu.2014.190 · Cited by 27
Pósfai, É. (2016) · The Anatolian Journal of Cardiology · doi:10.14744/anatoljcardiol.2015.6125 · Cited by 27
Abdulkarim, K., Samuelsson, J., Johansson, P. L., & Andréasson, B. (2017) · European Journal Of Haematology · doi:10.1111/ejh.12873 · Cited by 27
Dutta, A., Hutchison, R. E., & Mohi, G. (2017) · Blood · doi:10.1182/blood-2016-12-757344 · Cited by 27
Detection of the CALR mutation in the diagnosis of splanchnic vein thrombosis
Roques, M., Park, J., Minello, A., Bastie, J. N., & Girodon, F. (2014) · British Journal of Haematology · doi:10.1111/bjh.13235 · Cited by 27
Qiao, C., Sun, C., Ouyang, Y., Wang, J.-J., Qian, S.-X., Li, J., & Zhang, S. (2014) · Haematologica · doi:10.3324/haematol.2014.109199 · Cited by 26
Elliott, M. A., & Tefferi, A. (2015) · American Journal of Hematology · doi:10.1002/ajh.24284 · Cited by 26
Battista, V. D., Bochicchio, M. T., Giordano, G., Napolitano, M., & Lucchesi, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020561 · Cited by 27
Myeloproliferative disorders and their effects on bone homeostasis: the role of megakaryocytes
Karagianni, A., & Ravid, K. (2021) · Blood · doi:10.1182/blood.2021011480 · Cited by 26
Wang, N., Lysenkov, V. G., Orte, K. J., Kairisto, V., Aakko, J., Khan, S., & Elo, L. L. (2022) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1009269 · Cited by 27
Morsia, E., Torre, E., Poloni, A., Olivieri, A., & Rupoli, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094573 · Cited by 26
Targeting glutamine metabolism in myeloproliferative neoplasms
Zhan, H., Ciano, K., Dong, K., & Zucker, S. (2015) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2015.07.007 · Cited by 27
Essential Thrombocythemia: The Dermatologic Point of View
Cozzani, E., Iurlo, A., Merlo, G., Cattaneo, D., Burlando, M., Pierri, I., Gugliotta, L., & Parodi, A. (2015) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2015.08.086 · Cited by 26
Diagnosis and Management of Polycythemia Vera: Proceedings from a Multidisciplinary Roundtable.
Raedler, L. A. (2014) · Europe PMC (PubMed Central) · Cited by 26
Peptide Antibodies in Clinical Laboratory Diagnostics
Trier, N. H., & Houen, G. (2017) · Advances in clinical chemistry · doi:10.1016/bs.acc.2017.01.002 · Cited by 26
Mukherjee, S., Sathanoori, M., Ma, Z., Andreatta, M. E., Lennon, P. A., Wheeler, S. R., Prescott, J. L., Coldren, C. D., Casey, T. T., Rietz, H., et al. (2017) · Cancer Genetics · doi:10.1016/j.cancergen.2017.07.010 · Cited by 26
Diagnostic, Prognostic, and Predictive Utility of Recurrent Somatic Mutations in Myeloid Neoplasms
Patel, U., Luthra, R., Medeiros, L. J., & Patel, K. P. (2017) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2017.02.015 · Cited by 26
Gángó, A., Mózes, R., Boha, Z., Kajtár, B., Tímár, B., Király, P. A., Kiss, R., Fésüs, V., Nagy, N., Demeter, J., et al. (2018) · Leukemia Research · doi:10.1016/j.leukres.2017.12.005 · Cited by 26
Recent advances in the diagnosis and management of primary myelofibrosis
Takenaka, K., Shimoda, K., & Akashi, K. (2018) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2018.033 · Cited by 26
Ogasawara, A., Matsushita, H., Tanaka, Y., Shirasugi, Y., Ando, K., Asai, S., & Miyachi, H. (2018) · Clinica Chimica Acta · doi:10.1016/j.cca.2018.08.038 · Cited by 26
Rossi, C., Zini, R., Rontauroli, S., Ruberti, S., Prudente, Z., Barbieri, G., Bianchi, E., Salati, S., Genovese, E., Bartalucci, N., et al. (2018) · Molecular Oncology · doi:10.1002/1878-0261.12387 · Cited by 27
Paolino, G., Corsetti, P., Moliterni, E., Corsetti, S., Didona, D., Albanesi, M., Mattozzi, C., Lido, P., & Calvieri, S. (2019) · Giornale Italiano di Dermatologia e Venereologia · doi:10.23736/s0392-0488.17.05818-7 · Cited by 27
JAK/STAT in human diseases: a common axis in immunodeficiencies and hematological disorders
Djidjik, R., Mahammed, L. L., Berkani, L. M., Allam, I., Benmoussa, A. H., Gharnaout, M., & Belaid, B. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1669688 · Cited by 25
Leković, D., Gotić, M., Skoda, R. C., Beleslin‐Čokić, B. B., Milic, N. M., Ajtić, O. M., Nienhold, R., Šefer, D., Subotički, T., Kovačić, M. V., et al. (2016) · Annals of Hematology · doi:10.1007/s00277-016-2890-9 · Cited by 25
Al-Dewik, N. I. E., & Qoronfleh, M. W. (2019) · Advances in Public Health · doi:10.1155/2019/3807032 · Cited by 25
Surface-exposed and soluble calreticulin: conflicting biomarkers for cancer prognosis
Kepp, O., Liu, P., Zhao, L., Plo, I., & Kroemer, G. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1792037 · Cited by 26
Genetics of Myeloproliferative Neoplasms
Szybinski, J., & Meyer, S. C. (2021) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2020.12.002 · Cited by 28
CALR frameshift mutations in MPN patient-derived iPSCs accelerate maturation of megakaryocytes
Olschok, K., Han, L., Toledo, M. A. S., Böhnke, J., Graßhoff, M., Costa, I. G., Theocharides, A. P. A., Maurer, A., Schüler, H. M., Buhl, E. M., et al. (2021) · Stem Cell Reports · doi:10.1016/j.stemcr.2021.09.019 · Cited by 25
Essential Thrombocythemia in Children and Adolescents
Putti, M. C., Bertozzi, I., & Randi, M. L. (2021) · Cancers · doi:10.3390/cancers13236147 · Cited by 25
Clonal hematopoiesis and cardiovascular diseases: role of JAK2V617F
Misaka, T., Kimishima, Y., Yokokawa, T., Ikeda, K., & Takeishi, Y. (2022) · Journal of Cardiology · doi:10.1016/j.jjcc.2022.02.001 · Cited by 25
Schmidt, D., Endres, C., Hoefflin, R., Andrieux, G., Zwick, M., Karantzelis, N., Staehle, H. F., Vinnakota, J. M., Duquesne, S., Jovein, M. M., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-3553 · Cited by 25
CALR mutation screening in pediatric primary myelofibrosis
An, W., Wan, Y., Guo, Y., Chen, X., Ren, Y., Zhang, J., Chang, L., Wei, W., Zhang, P., & Zhu, X. (2014) · Pediatric Blood & Cancer · doi:10.1002/pbc.25211 · Cited by 25
Profile of pacritinib and its potential in the treatment of hematologic disorders
Hatzimichael, E. C., Tsolas, E., & Briasoulis, E. C. (2014) · Journal of Blood Medicine · doi:10.2147/jbm.s51253 · Cited by 25
Bjørn, M. E., Andersen, C. L., Jensen, M. K., & Hasselbalch, H. C. (2014) · European Journal Of Haematology · doi:10.1111/ejh.12332 · Cited by 25
Lundberg, P., Nienhold, R., Ambrosetti, A., Cervantes, F., Pérez‐Encinas, M., & Skoda, R. C. (2014) · Blood · doi:10.1182/blood-2014-01-550863 · Cited by 25
Pei, Y., Wu, Y., Wang, F., & Cui, W. (2016) · Annals of Hematology · doi:10.1007/s00277-016-2712-0 · Cited by 25
Martín–Llahí, M., Albillos, A., Bañares, R., Berzigotti, A., García‐Criado, Á., Genescà, J., Hernández–Gea, V., Llop‐Herrera, E., Masnou, H., Mateo, J., et al. (2017) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2017.03.011 · Cited by 25
Ferrer‐Marín, F., Arroyo, A. B., Bellosillo, B., Cuenca‐Zamora, E. J., Zamora, L., Hernández‐Rivas, J. M., Hernández‐Boluda, J. C., Fernández‐Rodríguez, C., Luño, E., Hernandez, C. G., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0767-3 · Cited by 25
Overview of Transgenic Mouse Models of Myeloproliferative Neoplasms (MPNs)
Dunbar, A. J., Nazir, A., & Levine, R. L. (2017) · Current Protocols in Pharmacology · doi:10.1002/cpph.23 · Cited by 27
Pérez‐Encinas, M., Sobas, M., Gómez‐Casares, M. T., Blanco, A. A., Pereira, M. S. N., Raya, J. M., Andrade‐Campos, M., Álvarez‐Larrán, A., Lewandowski, K. C., Szukalski, Ł., et al. (2020) · European Journal Of Haematology · doi:10.1111/ejh.13561 · Cited by 24
Splanchnic vein thrombosis associated with myeloproliferative neoplasms
Tremblay, D. A., Winters, A. C., Beckman, J. D., Naymagon, L., Patel, R. S., Mascarenhas, J. O., & Schiano, T. D. (2022) · Thrombosis Research · doi:10.1016/j.thromres.2022.08.003 · Cited by 24
Ng, J., Marneth, A. E., Griffith, A. M., Younger, D., Ghanta, S., Jiao, A. L., Willis, G. R., Han, J., Imani, J., Niu, B., et al. (2023) · Journal of Innate Immunity · doi:10.1159/000533732 · Cited by 25
The glutaminase inhibitor CB-839 targets metabolic dependencies of JAK2-mutant hematopoiesis in MPN
Usart, M., Hansen, N., Stetka, J., Fonseca, T. A., Guy, A., Kimmerlin, Q., Rai, S., Hao-Shen, H., Roux, J., Dirnhofer, S., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2023010950 · Cited by 24
Krähling, T., Balassa, K., Kiss, K. P., Bors, A., Bátai, Á., Halm, G., Egyed, M., Fekete, S., Reményi, P., Masszi, T., et al. (2015) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-15-0805 · Cited by 24
The molecular basis of myeloid malignancies
Kitamura, T., Inoue, D., Okochi, N., Kato, N., Komeno, Y., Yang, L. U., Enomoto, Y., Doki, N., UCHIDA, T., Kagiyama, Y., et al. (2014) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.90.389 · Cited by 26
Rapid and sensitive detection of CALR exon 9 mutations using high-resolution melting analysis
Lim, K., Lin, H., Chen, C. G., Wang, W., Chang, Y., Chiang, Y., Lin, C.-S., Su, N.-W., Su, Y., Lin, J., et al. (2014) · Clinica Chimica Acta · doi:10.1016/j.cca.2014.11.011 · Cited by 24
CALR mutations in patients with essential thrombocythemia diagnosed in childhood and adolescence
Giona, F., Teofili, L., Capodimonti, S., Laurino, M., Martini, M., Marzella, D., Palumbo, G., Diverio, D., Foà, R., & Larocca, L. M. (2014) · Blood · doi:10.1182/blood-2014-04-572040 · Cited by 24
Wang, X., Haylock, D. N., Hu, C. S., Kowalczyk, W., Jiang, T., Qiu, J., Mosoyan, G., Wu, H., Marshall, N., Mascarenhas, J. O., et al. (2016) · Blood · doi:10.1182/blood-2015-10-674465 · Cited by 26
Loghavi, S., Pemmaraju, N., Kanagal‐Shamanna, R., Mehrotra, M., Medeiros, L. J., Luthra, R., Lin, P., Huh, Y. O., Kantarjian, H. M., Cortes, J. E., et al. (2015) · Blood · doi:10.1182/blood-2015-03-632893 · Cited by 24
Lindgren, M., Samuelsson, J., Nilsson, L., Knutsen, H., Ghanima, W., Westin, J., Johansson, P. L., & Andréasson, B. (2018) · European Journal Of Haematology · doi:10.1111/ejh.13034 · Cited by 24
Variations in MHC class I antigen presentation and immunopeptidome selection pathways
Zaitouna, A. J., Kaur, A., & Raghavan, M. (2020) · F1000Research · doi:10.12688/f1000research.26935.1 · Cited by 24
Expression of CALR mutants causes mpl-dependent thrombocytosis in zebrafish
Lim, K.-H., Chang, Y.-C., Chiang, Y.-L., Lin, H.-C., Chang, C.-Y., Lin, C.-S., Huang, L., Wang, W.-T., Chen, C.-J., Chou, W.-C., et al. (2016) · Blood Cancer Journal · doi:10.1038/bcj.2016.83 · Cited by 24
Gleitz, H. F., Kramann, R., & Schneider, R. K. (2018) · The Journal of Pathology · doi:10.1002/path.5078 · Cited by 23
Calreticulin Mutations in Myeloproliferative Neoplasms
Lavi, N. (2014) · Rambam Maimonides Medical Journal · doi:10.5041/rmmj.10169 · Cited by 26
Harrison, C. N., Talpaz, M., & Mead, A. J. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2016.1195501 · Cited by 23
Araki, M., & Komatsu, N. (2017) · Cancer Science · doi:10.1111/cas.13327 · Cited by 23
Murine Models of Myelofibrosis
Jacquelin, S., Kramer, F., Mullally, A., & Lane, S. (2020) · Cancers · doi:10.3390/cancers12092381 · Cited by 26
Bennett, C., Lawrence, M., Guerrero, J. A., Stritt, S., Waller, A. K., Yan, Y., Mifsud, R. W., Ballester‐Beltrán, J., Baig, A., Mueller, A., et al. (2022) · Blood · doi:10.1182/blood.2021013113 · Cited by 23
Molecular Pathogenesis of Myeloproliferative Neoplasms
Rolles, B., & Mullally, A. (2022) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-022-00685-1 · Cited by 24
Kędzierska, M., & Bańkosz, M. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13237131 · Cited by 25
Åström, M., Hahn‐Strömberg, V., Zetterberg, E., Vedin, I., Merup, M., & Palmblad, J. E. W. (2014) · American Journal of Hematology · doi:10.1002/ajh.23907 · Cited by 23
How we diagnose and treat essential thrombocythaemia
Alimam, S., Wilkins, B. S., & Harrison, C. N. (2015) · British Journal of Haematology · doi:10.1111/bjh.13605 · Cited by 25
Co-existence ofJAK2V617F andCALRmutations in primary myelofibrosis
Zamora, L., Xicoy, B., Cabezón, M., Fernandez, C., Marcé, S., Vélez, P., Xandri, M., Gallardo, D., Millá, F., Feliú, E., et al. (2015) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2015.1015124 · Cited by 23
Screening PCR Versus Sanger Sequencing: Detection of CALR Mutations in Patients With Thrombocytosis
Jeong, J. H., Lee, H. T., Seo, J. Y., Seo, Y. H., Kim, K., Kim, M. J., Lee, J. H., Park, J., Hong, J. S., Park, P.-W., et al. (2016) · Annals of Laboratory Medicine · doi:10.3343/alm.2016.36.4.291 · Cited by 23
Koren‐Michowitz, M., Lavi, N., Ellis, M. H., Vannucchi, A. M., Mesa, R. A., & Harrison, C. N. (2016) · Annals of Hematology · doi:10.1007/s00277-016-2826-4 · Cited by 23
Mutations in myeloproliferative neoplasms – their significance and clinical use
Schischlik, F., & Královics, R. (2017) · Expert Review of Hematology · doi:10.1080/17474086.2017.1380515 · Cited by 24
Self-citationDriver mutations in primary myelofibrosis and their implications
Szuber, N., & Tefferi, A. (2017) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000406 · Cited by 23
Tashi, T., Swierczek, S. I., Kim, S. J., Salama, M. E., Song, J., Heikal, N., King, K. Y., Hickman, K., Litton, S., & Prchal, J. T. (2018) · Leukemia · doi:10.1038/s41375-018-0080-6 · Cited by 23
Metadata
- Authors
- Klampfl, T., Gisslinger, H., Harutyunyan, A. S., Nivarthi, H., Rumi, E., Milosevic, J. D., Them, N. C. C., Berg, T., Gisslinger, B., Pietra, D., Chen, D., Vladimer, G. I., Bagienski, K., Milanesi, C., Casetti, I. C., Sant'Antonio, E., Ferretti, V., Elena, C., Schischlik, F., Cleary, C., Six, M., Schalling, M., Schönegger, A., Bock, C., Malcovati, L., Pascutto, C., Superti-Furga, G., Cazzola, M., & Kralovics, R.
- Affiliations
- Austrian Academy of Sciences (AT)
- Medical University of Vienna (AT)
- Policlinico San Matteo Fondazione (IT)
- University of Pavia (IT)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-12-19
- Volume
- 369
- Issue
- 25
- Pages
- 2379-2390
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2157694607
- Cited by
- 2,003
- References
- 32
- Citations by year
- 2026: 80 · 2025: 63 · 2024: 81 · 2023: 117 · 2022: 122 · 2021: 173 · 2020: 144 · 2019: 146 · 2018: 153 · 2017: 200 · 2016: 247 · 2015: 243 · 2014: 222 · 2013: 7
- FWCI
- 118.00
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- INFM-OAR (INFN Catania) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Hematology › Myeloproliferative Neoplasms: Diagnosis and Treatment
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
- Keywords
- calreticulin, CALR mutation, myeloproliferative neoplasms, essential thrombocythemia, primary myelofibrosis, JAK2 V617F mutation, MPL mutation, somatic mutations, exon 9 deletion, frameshift mutation, STAT5 activation, thrombosis risk, overall survival
- MeSH terms
- Bone Marrow Diseases, Exons, Humans, Leukemia, Myeloid, Mutation, Thrombocythemia, Essential, Thrombosis, Proportional Hazards Models, Polymerase Chain Reaction, Sequence Analysis, DNA, Calreticulin, Janus Kinase 2, Receptors, Thrombopoietin, Primary Myelofibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
